Days at Home Among Dually Eligible Medicare Beneficiaries With Alzheimer Disease and Related Dementias - Report - MDSpire

Days at Home Among Dually Eligible Medicare Beneficiaries With Alzheimer Disease and Related Dementias

  • By

  • Yutong Zhang

  • Yang Yang

  • Johanna Thunell

  • Katherine E. M. Miller

  • July 9, 2026

  • 0 min

Share

Home Duration for Medicare and Medicaid Dual Eligibles with Alzheimer’s Disease

Overview

This study examines the variation in days at home among older adults dually eligible for Medicare and Medicaid with Alzheimer’s Disease and related dementias (ADRD). Findings indicate significant geographic differences in home duration.

Background

Dually eligible individuals represent a vulnerable population with high healthcare needs, particularly those with ADRD. Home- and community-based services (HCBS) are essential for supporting these individuals in aging in place. Understanding geographic variations in home duration is important for this population.

Data Highlights

StateMean Days at Home
Kentucky159.3
Alabama186.1
Rhode Island190.8
Missouri192.5
Washington275.4
California276.3
Oregon282.5
Alaska311.7

Key Findings

  • The study included 523,150 unique dually eligible PLWD with a mean age of 82 years.
  • Older dually eligible PLWD had a mean of 238.1 days at home in 2021.
  • HCBS users had a mean of 275.0 days at home.
  • Days at home varied significantly by state, from 159.3 days in Kentucky to 311.7 days in Alaska.
  • States like Alabama, Rhode Island, and Missouri had fewer than 195 days at home, while Washington, California, and Oregon had more than 270 days.
  • HCBS users had more days at home than the overall population, with state-specific variations.

Clinical Implications

The findings highlight the importance of HCBS in extending the time older adults with ADRD can remain at home. Geographic disparities in home duration may necessitate targeted interventions to improve access to HCBS across states.

Conclusion

This study highlights the significant variation in days at home among dually eligible PLWD.

Related Resources & Content

  1. Drugs - Real World Outcomes, 2015 -- Association Between Antipsychotic Medication and Nursing Home Placement in Dual-Eligible Medicare Recipients: A Propensity Score Analysis
  2. JAMA Network Open, 2023 -- Home Health Value-Based Purchasing and Postacute Home Health Visits Among Older Adults With Dementia
  3. American Journal of Epidemiology, 2023 -- Determining Medication Use Duration in Administrative Databases: A Guide Focused on Nursing Home Residents
  4. 2026 Alzheimer's disease facts and figures - PMC
  5. CMS Technical Instructions: Expectations for Dual-Eligible Beneficiaries
  6. GUIDE Model Frequently Asked Questions | CMS
  7. JAMA Network Open — Dementia and Hip Fracture Recovery—The Audacity of Home
  8. Guiding an Improved Dementia Experience by Clearing the Path for Comprehensive, High-Quality Dementia Care | CMS
  9. 2026 Alzheimer's disease facts and figures - PMC
  10. CMS Technical Instructions: Expectations for Dual-Eligible Beneficiaries
  11. GUIDE (Guiding an Improved Dementia Experience) Model | CMS
  12. GUIDE Model Frequently Asked Questions | CMS
  13. Health System, Community-Based, or Usual Dementia Care for Persons With Dementia and Caregivers: The D-CARE Randomized Clinical Trial | Trials | JAMA | JAMA Network
  14. Impact of Managed Long‐Term Services and Supports on Nursing Home Use - Bhaumik - 2026 - Journal of the American Geriatrics Society - Wiley Online Library
  15. Changes in Long-Term Care Markets: Assisted Living Capacity and the Prevalence of Nursing Home Residents With Dementia From 2019 to 2023 - ScienceDirect
  16. Time to nursing home admission and death in people with dementia: systematic review and meta-analysis - PMC

Original Source(s)

Related Content